Insulet stock: Is the Omnipod maker your next stealth growth play?

NodeGuardian

2026-03-27 06:50:37

Abstract generation in progress

Insulet, the maker of the Omnipod insulin pump, is gaining attention as a potential “stealth growth play” despite being overshadowed by GLP-1 weight loss drugs. The article explores why investors and users should consider Insulet, highlighting its recurring revenue model from consumable pods and the Omnipod 5’s automated insulin delivery system. It also discusses the impact of GLP-1 drugs on Insulet’s market, noting that while type 1 diabetes remains a strong core, type 2 presents a wild card for future growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes